Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Her primary care doctor had agreed the new class of weight loss drugs ... saying it could no longer fill tirzepatide past Dec. 2, 2024. In October, the FDA declared the drug shortage of ...

(The Hill) – Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in ... giant Eli Lilly. It falls in the same class ...

Additional 7.5 million Americans covered under Biden's plan The Biden Administration has announced that it wants to expand <a ...

Millions of Americans who have obesity could gain insurance coverage for drugs like Wegovy if the Trump administration allows ...